L-Theanine Use in Solitary Kidney with eGFR 61 mL/min/1.73 m²
L-theanine appears safe to use in patients with a solitary kidney and eGFR of 61 mL/min/1.73 m², as there is no evidence of nephrotoxicity and emerging data suggests potential nephroprotective properties.
Evidence Assessment
Lack of Contraindications in CKD Guidelines
The comprehensive KDIGO and KDOQI guidelines for CKD management do not list L-theanine among medications requiring dose adjustment, avoidance, or caution at any level of kidney function 1, 2, 3. These guidelines extensively detail cautionary agents including NSAIDs, metformin, antimicrobials, and numerous other medications that require modification in CKD, but L-theanine is notably absent from these lists 1, 4.
Potential Nephroprotective Effects
Recent preclinical evidence suggests L-theanine may actually provide kidney protection rather than harm:
Antioxidant mechanisms: In a murine model of drug-induced kidney injury, L-theanine pre-treatment significantly reduced serum creatinine (1.2 ± 0.3 mg/dL vs elevated levels in untreated nephrotoxic group) and BUN (34 ± 4 mg/dL) 5.
Histopathological improvement: L-theanine reduced tubular necrosis scores from 3.8 ± 0.3 to 1.6 ± 0.4, demonstrating substantial structural kidney protection 5.
Oxidative stress reduction: The compound lowered malondialdehyde levels and increased superoxide dismutase activity, indicating enhanced antioxidant defense mechanisms 5.
Considerations for Solitary Kidney Patients
Patients with solitary kidneys require special attention to avoid nephrotoxic exposures 6. The key management principles include:
Avoidance of nephrotoxic agents: NSAIDs should be avoided, and potentially nephrotoxic medications require careful monitoring 1, 6.
Dietary considerations: Protein intake should not exceed 1 g/kg/day, and sodium intake should be limited to <4 grams/day 6.
Regular monitoring: eGFR should be monitored regularly, though at 61 mL/min/1.73 m² (CKD stage G2-G3a), this patient has relatively preserved kidney function 2.
Clinical Recommendation
L-theanine can be used without specific dose adjustment or additional monitoring beyond standard CKD surveillance in this patient. The eGFR of 61 mL/min/1.73 m² places this patient in CKD stage G2-G3a, where most medications not specifically contraindicated can be used safely 2.
Important Caveats
Distinguish from other supplements: While L-theanine appears safe, other dietary supplements may pose risks in solitary kidney patients, including cranberry (increases oxalate and stone risk) and creatine (affects creatinine-based eGFR accuracy) 7.
Monitor kidney function: Continue routine eGFR monitoring as recommended for CKD patients (at least annually for this stage) 2.
Avoid nephrotoxic combinations: Ensure the patient avoids NSAIDs, high-dose protein supplements, and other established nephrotoxins that are contraindicated in solitary kidney patients 1, 6.
The absence of L-theanine from comprehensive nephrotoxicity lists, combined with emerging evidence of potential kidney protection, supports its safe use in this clinical scenario 1, 2, 5.